Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:00 PM EDTCompany ParticipantsWilliam Peters - ...

Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here

Amphastar faces declining sales in legacy products but expects mid- to high-single-digit revenue growth in 2026. Check out my ...
PharmiWeb

Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / March 4, 2026 / announced today that Bill Peters, CFO, and Dan Dischner, SVP of Corp. Communication, will be presenting at the Barclays 28th Annual Global ...
Insider Monkey

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.73 EPS, expectations were $0.97. Operator: Greetings, and welcome to the Amphastar Pharmaceuticals Fourth Quarter ...
Investing

Needham cuts Amphastar stock price target on Q4 miss, weak sales

Investing.com - Needham lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $30 from $34 while maintaining a Buy rating following the company’s fourth-quarter results. Despite the ...
Yahoo Finance

Amphastar Pharmaceuticals Inc (AMPH) Q4 2025 Earnings Call Highlights: Resilient Growth Amidst ...

Net Revenues: $719.9 million for the full year. BAQSIMI Revenue: $185.4 million, up 12% year over year. Primatene Mist Revenue: $108.7 million, up 7% year over year. Iron Sucrose Revenue: $4.4 million ...
Investing

Earnings call transcript: Amphastar’s Q4 2025 Misses Estimates, Stock Dips

Amphastar Pharmaceuticals reported its fourth-quarter 2025 earnings, revealing a significant miss in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS came in ...